EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

SARS ‐ CoV ‐2 antibody levels and long COVID occurrence in blood donors

Vivian I Avelino-Silva iD, Roberta Bruhn iD, Karla G Zurita, Xutao Deng, Elaine A Yu, Eduard Grebe iD, Mars Stone, Marion C Lanteri, Bryan R Spencer iD, Michael P Busch, Brian Custer iD

Transfusion · 2024-09 · 64 (9) · 1719-1731

DOI: 10.1111/trf.17952 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, online erschienen am 10.07.2024. Verfasst von Vivian I Avelino-Silva und 10 weiteren Autor:innen. Beteiligte Einrichtung: Vitalant Research Institute, California, San Francisco, USA. Hauptthemen laut MEDLINE: Blood Donors, COVID-19, SARS-CoV-2, Antibodies, Viral. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CDC HHS, Centers for Disease Control and Prevention.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long COVID is a common condition lacking consensus definition; determinants remain incompletely understood. Characterizing immune profiles associated with long COVID could support the development of preventive and therapeutic strategies.

Methods

We used a survey to investigate blood donors' infection/vaccination history and acute/persistent symptoms following COVID‐19. The prevalence of long COVID was evaluated using self‐report and an adapted definition from the RECOVER study. We evaluated factors associated with long COVID, focusing on anti‐spike and anti‐nucleocapsid SARS‐CoV‐2 antibodies. Lastly, we investigated long COVID clinical subphenotypes using hierarchical clustering.

Results

Of 33,610 participants, 16,003 (48%) reported having had COVID‐19; 1853 (12%) had self‐reported long COVID, 685 (4%) met an adapted RECOVER definition, and 2050 (13%) met at least one definition. Higher anti‐nucleocapsid levels measured 12–24 weeks post‐infection were associated with higher risk of self‐reported and RECOVER long COVID. Higher anti‐spike IgG levels measured 12–24 weeks post‐infection were associated with lower risk of self‐reported long COVID. Higher total anti‐spike measured 24–48 weeks post‐infection was associated with lower risk of RECOVER long COVID. Cluster analysis identified four clinical subphenotypes; patterns included neurological and psychiatric for cluster 1; neurological and respiratory for cluster 2; multi‐systemic for cluster 3; and neurological for cluster 4.

Discussion

Long COVID prevalence in blood donors varies depending on the adopted definition. Anti‐SARS‐CoV‐2 antibodies were time‐dependently associated with long COVID; higher anti‐nucleocapsid levels were associated with higher risk; and higher anti‐spike levels were associated with lower risk of long COVID. Different underlying pathophysiologic mechanisms may be associated with distinct clinical subphenotypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood DonorsCOVID-19SARS-CoV-2Antibodies, ViralHumansMaleFemaleMiddle AgedAdultImmunoglobulin GPost-Acute COVID-19 SyndromeSpike Glycoprotein, CoronavirusAged

Stichwörter der Autor:innen

COVID‐19COVID‐19 serological testingblood donorspost‐acute COVID‐19 syndrome

Substanzen

Antibodies, ViralImmunoglobulin GSpike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Vitalant Research Institute, California, San Francisco, USA.
  • Department of Epidemiology and Biostatistics, University of California San Francisco, California, San Francisco, USA.
  • Department of Laboratory Medicine, University of California San Francisco, California, San Francisco, USA.
  • South African Centre for Epidemiological Modeling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa.
  • Creative Testing Solutions, Tempe, Arizona, USA.
  • Scientific Affairs, American Red Cross, Rockville, Maryland, USA.

ORCID-Profile: Vivian I Avelino-Silva, Roberta Bruhn, Eduard Grebe, Bryan R Spencer, Brian Custer

Förderung

  • CDC HHS
  • Centers for Disease Control and Prevention

Zitieren

APA

Avelino-Silva, V. I., Bruhn, R., Zurita, K. G., Deng, X., Yu, E. A., Grebe, E., Stone, M., Lanteri, M. C., Spencer, B. R., Busch, M. P., & Custer, B. (2024). SARS ‐ CoV ‐2 antibody levels and long COVID occurrence in blood donors. Transfusion, 64(9), 1719-1731. https://doi.org/10.1111/trf.17952

Vancouver

Avelino-Silva VI, Bruhn R, Zurita KG, Deng X, Yu EA, Grebe E, et al. SARS ‐ CoV ‐2 antibody levels and long COVID occurrence in blood donors. Transfusion. 2024;64(9):1719-1731. doi:10.1111/trf.17952

BibTeX
@article{AvelinoSilva2024,
  author = {Avelino-Silva, Vivian I and Bruhn, Roberta and Zurita, Karla G and Deng, Xutao and Yu, Elaine A and Grebe, Eduard and Stone, Mars and Lanteri, Marion C and Spencer, Bryan R and Busch, Michael P and Custer, Brian},
  title = {SARS ‐ CoV ‐2 antibody levels and long COVID occurrence in blood donors},
  journal = {Transfusion},
  year = {2024},
  volume = {64},
  number = {9},
  pages = {1719--1731},
  doi = {10.1111/trf.17952}
}
Kostenlos starten →